StroMel

Phase 2Biologic

AAkan Biosciences, LLC

StroMel is one of 46 biologic programs targeting Osteoarthritis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteoarthritisNot yet recruiting

OsteoarthritisPhase 2

Not yet recruiting

Competition

Competitive Landscape

143 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Toradol

Roche

Preclinical

1 2

Cataflam

Bayer Aspirin

Enbrel

2 5

Glucophage

EMD Serono

Preclinical

1 6

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 7

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 8

Catapres

Boehringer Ingelheim

Preclinical

1 9

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 10

Chirocaine

PPurdue Pharma LP

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1/2Not yet recruiting

Osteoarthritis

NCT04750252

Clinical

Trials by Indication[1]

Osteoarthritis1 trial

Safety and Tolerability of StroMel™ in Subjects with Moderate to Severe Osteoarthritis of the Knee Joint

Not yet recruiting·AAkan Biosciences, LLC·Phase 1/2·NCT04750252·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for StroMel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — StroMel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for StroMel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Akan Biosciences, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: AAkan Biosciences, LLC

StroMel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Osteoarthritis1 trial

References

Drug Info

Quick Facts

Related News